IAP15 Rec'd PCT/PTO 2 6 MAY 2006

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 724615541 US Express Mail Label Number

26 May 2006 Date of Deposit

(REV 10-96		S. Department of Commerce Patent and Trademark Office	33316A								
	TRANSMITTAL LETTER TO	THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
	DESIGNATED/ELECTED	10/580895									
	CONCERNING A FILING U										
	NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED								
	P04/013419	25 November 2004 (25.11.04)	26 November 2003 (26.11.03)								
	OF INVENTION OSITIONS COMPRISING ORGANIC	COMPOUNDS									
	CANT(S) FOR DO/EO/US										
DESSE	T-BRETHES ET AL.										
Applica	nt herewith submits to the United States	Designated/Elected Office (DO/EO/US) th	ne following items and other information:								
3.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.										
5. 🖾	A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. (See Form PCT/IB/308) c. is not required, as the application was filed in the United States Receiving Office (RO/US).										
6.	A translation of the International Applica	ation into English (35 U.S.C. 371(c)(2)).	•								
7.	Amendments to the claims of the Interna. are transmitted herewith (require	ational Application under PCT Article 19 ed only if not transmitted by the Internation	(35 U.S.C.371(c)(3)). onal Bureau).								
	b. have been transmitted by the Ir	ternational Bureau.	•								
	c. have not been made; however,d. have not been made and will no	the time limit for making such amendment be made.	nts has NOT expired.								
8.	A translation of the amendments to the	claims under PCT Article 19 (35 U.S.C. 3									
9. 10.	An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).										
		•									
Items 1	1. to 16. below concern document(s) of	or information included.									
11. 🔲	An Information Disclosure Statement un	nder 37 CFR 1.97 and 1.98.									
12. 🔲	An assignment document for recording.	A separate cover sheet in compliance w	vith 37 CFR 3.28 and 3.31 is included.								
13. 🛭	A FIRST preliminary amendment. A SECOND or SUBSEQUENT prelimin	ary amendment.									
14.	An Application Data Sheet under 37 CF	R 1.76.									
15. 🔲	A substitute specification.										
16. 🗌	A change of power of attorney and/or a	ddress letter.									
17. 🔲	A computer-readable form of the seque	computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.									
18. 🛛	A second copy of the published Interna	tioṇal Application under 35 U.S.C. 154(d)	(4).								
19. 🗌	A second copy of the English language	translation of the International application	n under 35 U.S.C. 154(d)(4).								
20 🔯	Other items or information: Unsigned [Seclaration: Application Data Sheet									

AP20 Rec'd PCT/PTO 26 MAY 2006

U.S. APPLICATION NO. ATTORNEYS DO PCT/E P04/013419 ATTORNEYS DO 33316A						OCKET NUMBER					
The following fee	es are su	ıbmitted:							JLATIO	NS PTO USE	
		•						ONLY			
21. 🛮 Basic national fee											
22. Examination Fee											
If International preliminary examination report was prepared by USPTO											
and all claims satisfy provisions of PCT Article 33(1)-(4)											
23. Search fee											
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international											
application to the USPTO as an International Searching Authority \$ ☑ If International Search Report was prepared and provided to the Office \$400											
If International Search Report was prepared and provided to the Office											
								\$	900		
101AL OF 21, 22 AND 23											
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.											
Total Sheets	Extra			ch additional 50 or frac		R	ATE				
31 - 100 =		/50 =	thereof (round	d up to a whole number)	X \$	250	\$			
31 - 100 -		130 - 1		<u> </u>		ΛΨ	200	Ψ			
Surcharge of \$130 for furnishing the oath of declaration later than 30											
months from the earliest claimed priority date (37 CFR 1.492(e)). CLAIMS NUMBER FILED NUMBER EXTRA RATE											
Total claims		19	- 20 =	0	 x		50	\$			
Independent cla		1	-3 =	0	X		200	\$			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360									900		
TOTAL OF ABOVE CALCULATIONS = Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be								\$	300		
filed (Note 37 CFR 1.9, 1.27, 1.28).								\$			
SUBTOTAL =								\$	900		
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).								· .			
earliest claimed	priority C	Jale (37 CFF	(1.452(1)).	TO:	ΤΔΙ Ν	JATION	AL FEE =	\$	900		
Fee for recording	a the en	closed assig	nment (37 CF								
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$				
TOTAL FEES ENCLOSED =								\$	900		
									ount to	\$	
									unded narged	\$	
a Cl Ashaa	k in the	amount of \$_		to cover the above	faas is	enclosed			iai god		
		_		134 in the name of Nov			nt of \$000 to	cover th	a above	foor A	
duplica	ate copy	of this form is	s enclosed.								
			y authorized t 34 in the name	o charge any additional e of Novartis.	fees v	vhich may	be required,	or credit	any ove	erpayment to	
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
` "								+11/	1 //		
Send all correspondence to the address associated with Customer No. 001095, which is currently:							lter	4			
Mark Milstead											
Novartis Attorney for Applicants											
Corporate Intellectual Property Reg. No. 45,825 One Health Plaza, Building 104 (617) 871-4125							•				
East Hanover, NJ 07936-1080											
	Last Hallovel, No 07 300- 1000										